Dr. Carlos E. Sanchez to Lead Edwards Lifesciences TAVR Training
News related to:Edwards Lifesciences · 2 min read
MIAMI, October 8, 2026 /CourierPR/ -- Edwards Lifesciences has announced that interventional cardiologist Dr. Carlos E. Sanchez will serve as Program Faculty and Panelist for the company's Advanced Training for Implanters, an educational program designed for experienced transcatheter aortic valve replacement (TAVR) physicians. The two-day event, scheduled for October 8-9, 2026, at Fontainebleau Miami Beach, will gather approximately 31 experienced TAVR implanters from the Southeastern United States.
The program aims to provide an interactive platform for participants to engage in complex case discussions, treatment-strategy debates, and peer-to-peer exchanges. Dr. Sanchez, known for his expertise in transcatheter valve interventions and complex structural heart disease, will contribute his extensive experience to the program. His role will involve participating in presentations, complex case reviews, and panel debates focused on contemporary approaches to transcatheter valve therapy.
The curriculum of the Advanced Training for Implanters will cover a range of topics, including the management of severe aortic stenosis, complex bicuspid aortic valve disease, and TAVR durability and repeatability. Dr. Sanchez will also address procedural optimization and the complexities of lifetime management in TAVR, which considers the long-term implications of initial treatment strategies on future options.
The program is designed for physicians who already perform TAVR and emphasizes peer-to-peer discussion rather than introductory procedural instruction. The interactive format includes presentations, complex case reviews, treatment-strategy debates, and peer-to-peer discussion, providing a comprehensive learning experience for the participants.
The program will address contemporary topics in transcatheter valve therapy, including management strategies for severe aortic stenosis and evolving structural heart program considerations, contemporary clinical evidence and lifetime management of aortic stenosis, complex bicuspid aortic valve disease, mitral valve-in-valve and valve-in-ring interventions, TAVR durability, repeatability, and future coronary access, procedural optimization, and complex case reviews focused on procedural planning, anatomical considerations, and treatment strategy.
The program is expected to foster a collaborative environment where experienced TAVR implanters can share knowledge and best practices, ultimately improving patient outcomes. Dr. Sanchez's involvement in the program reflects his commitment to the advancement of TAVR and related therapies. His expertise in complex structural heart disease and advanced procedural imaging will undoubtedly contribute to the success of the event.
The program is designed to bring together approximately 31 experienced TAVR implanters, primarily from the Southeastern United States, for interactive discussions focused on complex cases, contemporary evidence, procedural strategy, and evolving questions in transcatheter valve therapy. The program will provide a platform for participants to engage in presentations, complex case reviews, treatment-strategy debates, and peer-to-peer discussion, ensuring a comprehensive learning experience for all attendees.